Equities analysts expect that Check Cap Ltd (NASDAQ:CHEK) will post earnings per share of ($0.54) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Check Cap’s earnings. Check Cap reported earnings of ($11.28) per share in the same quarter last year, which would indicate a positive year over year growth rate of 95.2%. The firm is scheduled to report its next earnings results on Wednesday, April 3rd.
According to Zacks, analysts expect that Check Cap will report full year earnings of ($2.57) per share for the current year. For the next year, analysts anticipate that the company will post earnings of ($1.40) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Check Cap.
Check Cap (NASDAQ:CHEK) last posted its quarterly earnings results on Monday, November 5th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.03.
NASDAQ CHEK opened at $3.22 on Monday. Check Cap has a 52-week low of $3.08 and a 52-week high of $19.78.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP purchased a new position in Check Cap during the third quarter worth about $141,000. Fosun International Ltd purchased a new position in Check Cap during the second quarter worth about $517,000. Finally, Renaissance Technologies LLC purchased a new position in Check Cap during the second quarter worth about $524,000. 1.55% of the stock is owned by hedge funds and other institutional investors.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Read More: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.